GBIO Key Statistics, Chart & Performance
The current stock price of GBIO is 5.22 USD. In the past month the price increased by 0.58%. In the past year, price decreased by -59.85%.
GBIO Latest News, Press Relases and Analysis
GBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.2 | 404.22B | ||
| AMGN | AMGEN INC | 15.55 | 183.17B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.35 | 116.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.06 | 75.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.43 | 61.48B | ||
| INSM | INSMED INC | N/A | 43.73B | ||
| NTRA | NATERA INC | N/A | 33.41B | ||
| BIIB | BIOGEN INC | 10.87 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.85B | ||
| INCY | INCYTE CORP | 15.65 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About GBIO
Company Profile
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
Company Info
GENERATION BIO CO
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Geoff McDonough
Employees: 115
Phone: 18575295908
GENERATION BIO CO / GBIO FAQ
Can you describe the business of GENERATION BIO CO?
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
What is the current price of GBIO stock?
The current stock price of GBIO is 5.22 USD. The price decreased by -0.19% in the last trading session.
What is the dividend status of GENERATION BIO CO?
GBIO does not pay a dividend.
What is the ChartMill rating of GENERATION BIO CO stock?
GBIO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is GENERATION BIO CO (GBIO) stock traded?
GBIO stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for GENERATION BIO CO?
The Revenue of GENERATION BIO CO (GBIO) is expected to decline by -41.57% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
GBIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GBIO. When comparing the yearly performance of all stocks, GBIO is a bad performer in the overall market: 92.1% of all stocks are doing better.
GBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GBIO. GBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GBIO Financial Highlights
Over the last trailing twelve months GBIO reported a non-GAAP Earnings per Share(EPS) of -9.34. The EPS decreased by -32.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.38% | ||
| ROE | -123.87% | ||
| Debt/Equity | 0 |
GBIO Forecast & Estimates
12 analysts have analysed GBIO and the average price target is 30.94 USD. This implies a price increase of 492.72% is expected in the next year compared to the current price of 5.22.
For the next year, analysts expect an EPS growth of -27.52% and a revenue growth -41.57% for GBIO